CANTA.ST Stock - Cantargia AB (publ)
Unlock GoAI Insights for CANTA.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-3,438,000 | $-3,451,000 | $-3,692,000 | $-3,446,000 | $-3,248,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-168,583,000 | $-290,017,000 | $-381,549,000 | $-370,267,000 | $-173,945,000 |
| Net Income | $-161,654,000 | $-280,027,000 | $-371,814,000 | $-366,504,000 | $-173,085,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.88 | $-1.65 | $-2.90 | $-3.66 | $-1.61 |
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
Visit WebsiteEarnings History & Surprises
CANTA.STEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Feb 20, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 19, 2025 | $-0.18 | $1.07 | +694.4% | ✓ BEAT |
Q3 2025 | Aug 21, 2025 | — | $-0.16 | — | — |
Q2 2025 | May 13, 2025 | — | $-0.26 | — | — |
Q1 2025 | Feb 21, 2025 | — | $-0.21 | — | — |
Q4 2024 | Nov 15, 2024 | — | $-0.23 | — | — |
Q3 2024 | Aug 27, 2024 | — | $-0.24 | — | — |
Q2 2024 | May 21, 2024 | — | $-0.20 | — | — |
Q1 2024 | Feb 22, 2024 | $-0.43 | $-0.40 | +7.0% | ✓ BEAT |
Q4 2023 | Nov 10, 2023 | $-0.45 | $-0.46 | -2.2% | ✗ MISS |
Q3 2023 | Aug 22, 2023 | $-0.48 | $-0.34 | +29.2% | ✓ BEAT |
Q2 2023 | May 23, 2023 | $-0.47 | $-0.45 | +4.3% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | — | $-0.71 | — | — |
Q4 2022 | Nov 10, 2022 | — | $-0.44 | — | — |
Q3 2022 | Aug 30, 2022 | — | $-0.63 | — | — |
Q2 2022 | May 23, 2022 | — | $-0.94 | — | — |
Q1 2022 | Feb 24, 2022 | — | $-0.87 | — | — |
Q4 2021 | Nov 11, 2021 | — | $-0.86 | — | — |
Q3 2021 | Aug 19, 2021 | — | $-0.59 | — | — |
Latest News
Frequently Asked Questions about CANTA.ST
What is CANTA.ST's current stock price?
What is the analyst price target for CANTA.ST?
What sector is Cantargia AB (publ) in?
What is CANTA.ST's market cap?
Does CANTA.ST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CANTA.ST for comparison